These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23533606)

  • 1. Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection.
    Zoufaly A; Cramer JP; Vettorazzi E; Sayk F; Bremer JP; Koop I; de Weerth A; Schmiedel S; Jordan S; Fraedrich K; Asselborn NH; Nitschke M; Neumann-Grutzeck C; Magnus T; Rüther C; Fellermann K; Stahl RK; Wegscheider K; Lohse AW
    PLoS One; 2013; 8(3):e59209. PubMed ID: 23533606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
    Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical composite risk score for the development of Haemolytic Uraemic Syndrome from Shiga toxin-producing Escherichia coli.
    Hamilton D; Cullinan J
    Eur J Public Health; 2019 Oct; 29(5):861-868. PubMed ID: 31326985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of age and sex with the clinical outcome and incubation period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011.
    Werber D; King LA; Müller L; Follin P; Buchholz U; Bernard H; Rosner B; Ethelberg S; de Valk H; Höhle M
    Am J Epidemiol; 2013 Sep; 178(6):984-92. PubMed ID: 23935124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
    Dammermann W; Mihajlov V; Middendorf B; Mellmann A; Karch H; Lüth S; Ullrich S
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1353-1356. PubMed ID: 29280264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic-Uremic Syndrome and Escherichia coli O121 at a Lake in Connecticut, 1999.
    McCarthy TA; Barrett NL; Hadler JL; Salsbury B; Howard RT; Dingman DW; Brinkman CD; Bibb WF; Cartter ML
    Pediatrics; 2001 Oct; 108(4):E59. PubMed ID: 11581467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
    Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
    Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.
    Nitschke M; Sayk F; Härtel C; Roseland RT; Hauswaldt S; Steinhoff J; Fellermann K; Derad I; Wellhöner P; Büning J; Tiemer B; Katalinic A; Rupp J; Lehnert H; Solbach W; Knobloch JK
    JAMA; 2012 Mar; 307(10):1046-52. PubMed ID: 22416100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.
    McKee RS; Schnadower D; Tarr PI; Xie J; Finkelstein Y; Desai N; Lane RD; Bergmann KR; Kaplan RL; Hariharan S; Cruz AT; Cohen DM; Dixon A; Ramgopal S; Rominger A; Powell EC; Kilgar J; Michelson KA; Beer D; Bitzan M; Pruitt CM; Yen K; Meckler GD; Plint AC; Bradin S; Abramo TJ; Gouin S; Kam AJ; Schuh A; Balamuth F; Hunley TE; Kanegaye JT; Jones NE; Avva U; Porter R; Fein DM; Louie JP; Freedman SB;
    Clin Infect Dis; 2020 Apr; 70(8):1643-1651. PubMed ID: 31125419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic Uremic Syndrome: A Contemporary Pediatric Experience.
    Alfandary H; Rinat C; Gurevich E; Eisenstein I; Goldberg O; Kropach N; Landau D
    Nephron; 2020; 144(3):109-117. PubMed ID: 31935726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS).
    Lukasz A; Beneke J; Menne J; Vetter F; Schmidt BM; Schiffer M; Haller H; Kümpers P; Kielstein JT
    Thromb Haemost; 2014 Feb; 111(2):365-72. PubMed ID: 24172823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.
    Kakoullis L; Papachristodoulou E; Chra P; Panos G
    J Infect; 2019 Aug; 79(2):75-94. PubMed ID: 31150744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli.
    Mody RK; Luna-Gierke RE; Jones TF; Comstock N; Hurd S; Scheftel J; Lathrop S; Smith G; Palmer A; Strockbine N; Talkington D; Mahon BE; Hoekstra RM; Griffin PM
    Arch Pediatr Adolesc Med; 2012 Oct; 166(10):902-9. PubMed ID: 22869280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011.
    King LA; Nogareda F; Weill FX; Mariani-Kurkdjian P; Loukiadis E; Gault G; Jourdan-DaSilva N; Bingen E; Macé M; Thevenot D; Ong N; Castor C; Noël H; Van Cauteren D; Charron M; Vaillant V; Aldabe B; Goulet V; Delmas G; Couturier E; Le Strat Y; Combe C; Delmas Y; Terrier F; Vendrely B; Rolland P; de Valk H
    Clin Infect Dis; 2012 Jun; 54(11):1588-94. PubMed ID: 22460976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection].
    Rivas M; Balbi L; Miliwebsky ES; García B; Tous MI; Leardini NA; Prieto MA; Chillemi GM; de Principi ME
    Medicina (B Aires); 1998; 58(1):1-7. PubMed ID: 9674201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
    Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
    Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.